B. Riley Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $155

Benzinga Newsdesk www.benzinga.com Positive 84.4%

Neg 0% Neu 0% Pos 84.4%

B. Riley Securities analyst Kalpit Patel maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $117 to $155.